OP0026 Induction of Clinical Remission Followed by Drug-Free Withdrawal with Abatacept Combination and Monotherapy in Early RA: Results from the AVERT Study over 18 Months

Paul Emery ,Daniel E Fürst ,Burgio Gr ,Dennis A Wong ,Emilie Barré ,Vivian P Bykerk ,Chetan S Karyekar ,B Combe,Tom W J Huizinga

doi:10.1136/annrheumdis-2014-eular.2132

OP0026 Induction of Clinical Remission Followed by Drug-Free Withdrawal with Abatacept Combination and Monotherapy in Early RA: Results from the AVERT Study over 18 Months

Paul Emery , Daniel E Fürst + Show 7 more

https://doi.org/10.1136/annrheumdis-2014-eular.2132

Copy DOI

Journal: Annals of the Rheumatic Diseases	Publication Date: Jun 1, 2014
Citations: 3

Affiliation: University of Leeds, University of California, Los Angeles, Charité - Universitätsmedizin Berlin, Bristol-Myers Squibb (United States), Bristol-Myers Squibb (Belgium), Hospital for Special Surgery, Leiden University Medical Center

#Abatacept Monotherapy #Abatacept + Show 8 more

Abstract
Full-Text
Similar Papers

Abstract

BackgroundAVERT (Assessing Very Early Rheumatoid arthirits Treatment) is a Phase IIIb, randomized, active-controlled study to evaluate the efficacy and safety of subcutaneous (SC) abatacept (ABA) in pts with early RA.ObjectivesTo...

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Annals of the Rheumatic Diseases

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.